$2.17+1.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
Editas Medicine licenses gene-editing technology to drug companies and develops experimental medicines for people with serious diseases.
Just reported
From Editas Medicine, Inc.'s results release of November 9, 2026; its quarterly report has since been filed.
Actual
$10.4M
+37% y/y
-13% q/q
Guided
—
No guide given
Actual
-$0.15
Guided
—
No guide given
Actual
-$24.3M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $10.4M | $7.5M | +37.41% |
| Profit | -$23.4M | -$25.1M | +6.86% |
| Profit per share | -$0.15 | -$0.28 | +46.43% |
| Free Cash Flow | -$21.2M | -$31.3M | +32.25% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Editas Medicine, Inc. reported on November 9, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing medicine for hyperlipidemia, towards the clinic,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
EDIT-401 is an experimental, potentially best-in-class in vivo gene editing medicine, based on Editas’ differentiated upregulation approach. EDIT-401 is designed to treat hyperlipidemia by directly editing the LDLR gene to increase LDLR protein expression and reduce LDL-C levels. This targeted approach has demonstrated a favorable preclinical profile in both efficacy data and tolerability and supports the potential of EDIT-401 to deliver meaningful clinical outcomes for patients underserved by current lipid-lowering therapies.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Editas Medicine, Inc.’s Item 2.02 8-K filed November 9, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.